NAMS Stock NewAmsterdam Pharma Company N.V.
US · NasdaqGMLast in our picks 2026-10-20 — not in the current list; analysis below is from that screen
Promising cardiovascular drug development and strong analyst targets offer substantial upside.
Future value: $53.00 (+158.92%) · 6-12 months
Signal breakdown
- ▸Consensus Strong Buy; Wells Fargo maintained Buy at $55.
- ▾Below 50-day MA (-15.54%)
- ▾Near 52-week low (3.9% of range)
- ▸~159% upside to price target
Is NAMS a buy right now?
Trend: NAMS is trading below the 50-day average (-16.38%), RSI 44 — neutral momentum, with a 3-month return of -34.78%.
Valuation & quality: NewAmsterdam Pharma Company N.V. trades on forward P/E -12.8, price-to-book 3.64; fundamentals show net margin 0.0%, return on equity -36.8%, revenue growth -80.7% year on year.
Analyst consensus: 14 analysts have a mean 12-month price target of $49.84 (+155.2% vs the last close; range $37.94 – $59.18), consensus rating “strong buy”.
Our screen: BUY (score 3) — Promising cardiovascular drug development and strong analyst targets offer substantial upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -9.70% | -10.80% | +17.90% | +0.60% | -18.00% | -8.80% | -4.00% | -19.00% |
Fundamentals
Analyst price target
Technical signals
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
Sector: Healthcare · Industry: Biotechnology · Netherlands · 100 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.